Evergreen Therapeutics is a global innovative pharmaceutical company established in 2019 that features artificial intelligence (AI) as one of its core technologies. The company has offices and laboratories in Maryland, USA and Shenzhen, China. Evergreen’s team consists of top talents with expertise ranging from drug discovery to clinical development. As a pharmaceutical company rich in clinical knowledge and international regulatory experiences, Evergreen is committed in using AI technologies to develop drug products for “unmet medical needs”. At present, Evergreen's pipeline contains 10 programs, five of which have already entered phase I to III clinical stages in the United States. Evergreen has more than 50 patent applications, covering major global pharmaceutical markets including China, the United States, Europe, and Japan.

Evergreen has established dual-buiness model operation – not only is it able to develop its own drug candidates, it is also able to use its AI-empowered technologies to provide R&D support to other biopharmaceutical companies. In order to work with other companies, Evergreen has been focusing solely in the development of drug products for the treatment of diseases in ophthalmology, autoimmunity, and obstetrics; while for other therapeutic areas, the company relies on its AI technology and international regulatory service capabilities to help its clients to design late stage clinical studies, identify suitable clinical biomarkers, and apply for one of FDA’s expedited programs (eg. fast track, breakthrough, priority review, and accelerated approval). Currently, the company is establishing a laboratory that will be able to combine the results of “wet” and “dry” experiments. By using this laboratory, Evergreen will be able to optimize the processes of biomarker screening, selection of clinical indications，and predication of clinical study outcomes. The goal of Evergreen’s approach is to improve the efficiency and success rate of drug development for the entire pharmaceutical industry.